Neuroscientific Biopharmaceuticals (ASX:NSB) Current Deferred Revenue: A$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neuroscientific Biopharmaceuticals Current Deferred Revenue?

Neuroscientific Biopharmaceuticals ASX:NSB +1.69% Current Deferred Revenue is A$0.00 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Neuroscientific Biopharmaceuticals's current deferred revenue for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Neuroscientific Biopharmaceuticals Current Deferred Revenue Related Terms

Neuroscientific Biopharmaceuticals Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Neuroscientific Biopharmaceuticals's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuroscientific Biopharmaceuticals Current Deferred Revenue Chart

Neuroscientific Biopharmaceuticals Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Current Deferred Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Neuroscientific Biopharmaceuticals Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
What does a Current Deferred Revenue of A$0.00 Mil mean?
Neuroscientific Biopharmaceuticals (ASX:NSB) has a Current Deferred Revenue of A$0.00 Mil as of Dec. 2025. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Neuroscientific Biopharmaceuticals and its competitors.
Is Neuroscientific Biopharmaceuticals' Current Deferred Revenue too high?
Neuroscientific Biopharmaceuticals' current Current Deferred Revenue is A$0.00 Mil.
How does Neuroscientific Biopharmaceuticals' Current Deferred Revenue compare to VRTX and REGN?
Neuroscientific Biopharmaceuticals' Current Deferred Revenue of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Neuroscientific Biopharmaceuticals and its competitors. Neuroscientific Biopharmaceuticals's current Current Deferred Revenue is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuroscientific Biopharmaceuticals stock overvalued right now?
Neuroscientific Biopharmaceuticals (ASX:NSB) has a current Current Deferred Revenue of A$0.00 Mil. The current Current Deferred Revenue is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Neuroscientific Biopharmaceuticals (ASX:NSB), the current Current Deferred Revenue is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neuroscientific Biopharmaceuticals Business Description

Address 216 Street Georges Terrace, Level 4, Perth, WA, AUS, 6000
Neuroscientific Biopharmaceuticals Ltd is an Australian-based biotechnology company. The company is engaged in the development of diagnostic and treatments for neurodegenerative diseases through preclinical studies of patented technologies.